Bank of America Corp DE Boosts Stake in Sana Biotechnology, Inc. (NASDAQ:SANA)

Bank of America Corp DE lifted its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 11.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,131,813 shares of the company's stock after purchasing an additional 115,347 shares during the quarter. Bank of America Corp DE owned 0.51% of Sana Biotechnology worth $1,845,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in shares of Sana Biotechnology during the 4th quarter worth approximately $34,000. Ameriprise Financial Inc. bought a new position in shares of Sana Biotechnology during the fourth quarter valued at $29,000. Boxer Capital Management LLC bought a new position in Sana Biotechnology during the fourth quarter worth $2,518,000. Jane Street Group LLC raised its stake in Sana Biotechnology by 287.2% during the fourth quarter. Jane Street Group LLC now owns 367,855 shares of the company's stock worth $600,000 after buying an additional 272,862 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Sana Biotechnology by 5.3% during the fourth quarter. Northern Trust Corp now owns 1,188,346 shares of the company's stock worth $1,937,000 after buying an additional 60,004 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Stock Performance

Sana Biotechnology stock traded up $0.23 during midday trading on Thursday, reaching $2.55. 6,256,061 shares of the stock were exchanged, compared to its average volume of 3,493,801. The company's fifty day moving average is $1.79 and its 200-day moving average is $2.33. The firm has a market cap of $574.97 million, a PE ratio of -1.82 and a beta of 1.78. Sana Biotechnology, Inc. has a 52 week low of $1.26 and a 52 week high of $7.89.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. On average, sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SANA. HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of Sana Biotechnology in a research report on Thursday, April 24th. Citizens Jmp upgraded shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price target on the stock in a research note on Tuesday, March 18th. Finally, Jefferies Financial Group started coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They set a "buy" rating and a $7.00 price target on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $10.80.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.